Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes

References

• WillsonTMLambertMHKliewerSAPeroxisome proliferator-activated receptorgamma and metabolic diseaseAnnu Rev Biochem20017034136711395411
   PubMed Web of Science ®Google Scholar
• StumvollMHaringHUGlitazones: clinical effects and molecular mechanismAnn Med200234321722412173692
   PubMed Web of Science ®Google Scholar
• YamanouchiTSakaiTIgarashiKIchiyanagiKWatanabeHKawasakiTComparison of metaboric effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetesDiabet Med200522898098516026361
   PubMed Web of Science ®Google Scholar
• TanMJohnsDGálvezGGfor the GLAD Study GroupEffects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trialClin Ther200426568069315220012
   PubMed Web of Science ®Google Scholar
• PfütznerAForstTPioglitazone-an antidiabetic drug with the potential to reduce cardiovascular mortalityExpert Opin Pharmacother20067446347616503818
   PubMed Web of Science ®Google Scholar
• RosenstockJEinhornDHershonKGlazerNBYuSthe Pioglitazone 014 Study GroupEfficacy and safety of pioglitazone in type 2 diabetes: A randomized, placebo-controlled study in patients receiving stable insulin therapyInt J Clin Pract200256425125712074206
   PubMed Web of Science ®Google Scholar
• DavidsonJAPerezAZhangJThe Pioglitazone 343 Study GroupAddition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized studyDiabetes Obes Metab20068216417416448520
   PubMed Web of Science ®Google Scholar
• RaskinPRendellMRiddleMCDoleJFFreedMIRosenstockJRosiglitazone Clinical Trials Study GroupA randomized trial of rosiglitazone therapy in patient with inadequately controlled insulin-treated type 2 diabetesDiabetes Care20012471226123211423507
   PubMed Web of Science ®Google Scholar
• FernandezMTriplittCWajcbergEAddition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanismsDiabetes Care200831112112717909084
   PubMed Web of Science ®Google Scholar
• ReavenGMHollenbeckCJengCYWuMSChenYDMeasurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDMDiabets198837810201024
   PubMed Web of Science ®Google Scholar
• BodenGChenXUrbainJLEvidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose productionDiabetes1996458104410508690150
   PubMed Web of Science ®Google Scholar
• OakesNDThalenPGJacintoSMLjungBThiazolidinediones increase plasma-adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availabilityDiabetes20015051158116511334421
   PubMed Web of Science ®Google Scholar
• MiyazakiYMahankaliAMatsudaMImproved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazoneDiabetes Care200124471071911315836
   PubMed Web of Science ®Google Scholar
• KishimotoMYamasakiYKubotaM1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDMDiabetes Care1995188115611597587851
   PubMed Web of Science ®Google Scholar
• YamanouchiTInoueTOgataEPost-load glucose measurements in oral glucose tolerance tests correlate well with 1,5-anhydroglucitol, an indicator of overall glycemic state, in subjects with impaired glucose toleranceClin Sci2001101322723311524039
   PubMed Web of Science ®Google Scholar
• AsnaniSKunhiramanBJawaAAkersDLumpkinDFonsecaVPioglitazone restores endothelial function in patients with type 2 diabetes treated with insulinMetab Syndr Relat Disord20064317918418370736
   PubMedGoogle Scholar
• RatzIStranksSFilipczakREfficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: An 18-week, randomized, open-label studyClin Ther20052791432144316291416
   PubMed Web of Science ®Google Scholar
• HermansonKColomboMStorgaardHImproved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetesDiabetes Care200225588388811978685
   PubMed Web of Science ®Google Scholar
• RaskinPAllenEHollanderPfor the INITIATE Study GroupInitiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogsDiabetes Care200528226026515677776
   PubMed Web of Science ®Google Scholar
• MattooVEcklandDWidelMMetabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group studyClin Ther200527555456715978304
   PubMed Web of Science ®Google Scholar
• BerhanuPPerezAYuSEffect of pioglitazone in combination with insulin therapy on glycemic control, insulin dose requirement and lipid profile with type 2 diabetes previously poorly controlled with combination therapyDiabetes Obes Metab20079451252017587394
   PubMed Web of Science ®Google Scholar
• GoldbergRBKendallDMDeegMAA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dislipidemiaDiabetes Care20052871547155415983299
   PubMed Web of Science ®Google Scholar
• BuseJBTanMHPrinceMJEricksonPPThe effects of oral antihyperglycemic medications on serum lipid profiles in patients with type 2 diabetesDiabetes Obes Metab20046213315614746579
   PubMed Web of Science ®Google Scholar
• LamarcheBSt PierreACRuelILCantinBA prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in menCan J Cardiol200117885986511521128
   PubMed Web of Science ®Google Scholar
• BuseJBGumbinerBMathiasNPfor the Troglitazone insulin study group. Troglitazone use in insulin-treated type 2 diabetic patientsDiabetes Care1998219145514619727891
   PubMed Web of Science ®Google Scholar
• StrowigSMAviles-SantaMLRaskinPComparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetesDiabetes Care200225101691169812351463
   PubMed Web of Science ®Google Scholar
• NataliABaldewegSToschiEVascular effects of improving metabolic control with metformin/rosiglitazone in type 2 diabetesDiabetes Care20042761349135715161787
   PubMed Web of Science ®Google Scholar
• PfütznerAMarxNLubbenGImprovement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer StudyJ Am Coll Cardiol200545121925193115963388
   PubMed Web of Science ®Google Scholar
• WajcbergEStiwijilkamolAMusiNDeFronzoRCersosimoERelationshiop between vascular reactivity and lipids in Mexican American with T2DM treated with pioglitazoneJ Clin Endoclinol Metab200792412561262
   PubMed Web of Science ®Google Scholar
• HohbergCPfütznenAForstTSuccessful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes with residual β-cell function: results from the PioSwitch StudyDiabetes Obes Metab200911546447119422402
   PubMed Web of Science ®Google Scholar
• PotenzaMAAddabboFMontagnaniMVascular actions of insulin with implications for endothelial dysfunctionAm J Physiol Endocrinol Metab20092973E568E57719491294
   PubMed Web of Science ®Google Scholar
• DandonaPAjadaAMohantyPInsulin inhibits intra-nuclear factor κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?J Clin Endocrinol Metab20018673257326511443198
   PubMed Web of Science ®Google Scholar
• EvansJLGoldfineIAMadduxBAGrodskyGMOxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetesEndcr Rev2002235599622
   PubMed Web of Science ®Google Scholar
• Van den BergheGHow dose blood glucose control with insulin saves lives in intensive care?J Clin Invest200411491187119515520847
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation: Guideline for management of postmeal glucose. 2007Available from: www.idf.org
   Google Scholar
• CerielloAEspositoKPiconiLOscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patientsDiabetes20085751349135418299315
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROactive pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet200536694931279128916214598
   PubMed Web of Science ®Google Scholar
• ScheenAJCombined thiazolidinedione-insulin therapy. Should we be concerned about safety?Drug Safety2004271284185615366973
   PubMed Web of Science ®Google Scholar
• SchwartzSRaskinPFonsecaVGravelineJFEffect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study GroupN Engl J Med1998338138618669516220
   PubMed Web of Science ®Google Scholar
• ScheenACharbonnelBBelgiumLFranceNReduced insulin requirements and improved glycemic control with pioglitazone in insulin-treated patients with type 2 diabetes: results from PROactiveADA 66th Scientific Sessions2006561-P
   Google Scholar
• CryerPEDavisSNHypoglycemia in diabetesDiabetes Care20032661902191212766131
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study GroupGersteinHCMillerMEByingtonRPEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• SkylerJSBergenstalRBonowROIntensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA diabetes trialsDiabetes Care200932118719219092168
   PubMed Web of Science ®Google Scholar
• BellDSHUnilateral edema due to a thiazolidinediones [letter]Diabetes Care2003269270012941750
   PubMedGoogle Scholar
• SinghSLokeYKFurbergCDThiazolidinediones and heart failureDiabetes Care20073082148215317536074
   PubMed Web of Science ®Google Scholar
• LagoRMSinghPPNestoRWCongestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trialsLancet200737095931129113617905165
   PubMed Web of Science ®Google Scholar
• DeFronzoRAThe effect of insulin on renal sodium metabolism: a review with clinical implicationsDiabetologia19812131651717028550
   PubMed Web of Science ®Google Scholar
• MuscelliENataliABianchiSEffect of insulin on renal sodium and uric acid handling in essential hypertensionAm J Hypertens1996987467528862220
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJWolskiKComparison of pioglitazone vs. glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. The PERISCOPE randomized control trialJAMA2008299131561157318378631
   PubMed Web of Science ®Google Scholar
• DeleaTEEdelsbergJSHagiwaraMUse of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort studyDiabetes Care200326112983298914578227
   PubMed Web of Science ®Google Scholar
• KermaniAGargAThiazolidinedione-associated congestive heart failure and pulmonary edemaMayo Clin Proc20037891088109112962163
   PubMed Web of Science ®Google Scholar
• ChengAYFantusIGThiazolidinedione-induced congestive heart failureAnn Pharmacother200438581782015039476
   PubMed Web of Science ®Google Scholar
• GhazziMNPerezJEAntonucciTKthe Troglitazone Study GroupCardiac and glycemic benefits of troglitazone treatment in NIDDMDiabetes19974634334399032099
   PubMed Web of Science ®Google Scholar
• St John SutlonMRendallMDandonaPA comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetesDiabetes Care200225112058206412401757
   PubMed Web of Science ®Google Scholar
• OgawaSTakeuchiKItoSPlasma BNP levels in the treatment of type 2 diabetes with pioglitazoneJ Clin Endocrinol Metab20038883993399612915698
   PubMed Web of Science ®Google Scholar
• ShirabeSSasamotoKArakiABNP elevation following 12-week pioglitazone treatment in patients with type 2 diabetesDiabetologia200952Suppl 1S335
   Google Scholar
• NiemeyerNVJanneyLMThiazolidinedione-induced edemaPharmacotherapy200222792492912126225
   PubMed Web of Science ®Google Scholar
• FukunagaYItohHDoiKThiazolidinediones, peroxisome proliferator-activated receptor-gamma agonists, regulate endothelial cell growth and secretions of vasoactive peptidesAtherosclerosis2001158111311911500181
   PubMed Web of Science ®Google Scholar
• EmotoMAnnoTSatoYTroglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipositiesDiabetes20015051166117011334422
   PubMed Web of Science ®Google Scholar
• DuanSZUsherMGMortensenRMPeroxisome proliferator-activated receptor-gamma-mediated effects in the vasculatureCirc Res2008102328329418276926
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJWolskiKComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes. The PERISCOPE Randomized Controlled TrialJAMA2008299131561157318378631
   PubMed Web of Science ®Google Scholar
• Yki-JärvinenHThiazolidinedionesN Engl J Med2004351111106111815356308
   PubMed Web of Science ®Google Scholar
• ChilcottJTappendenPLloydJMA systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitusClin Ther200123111792182311768834
   PubMed Web of Science ®Google Scholar
• ShimizuHTsuchiyaTSatoNTroglitazone reduces plasma leptin concentrations but increases hunger in NIDDM patientsDiabetes Care1998219147014749727893
   PubMed Web of Science ®Google Scholar
• MiyazakiYMahankaliAMatsudaMEffect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patientsJ Clin Endocrinol Metab20028762784279112050251
   PubMed Web of Science ®Google Scholar
• ShadidSJensenMDEffects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesityDiabetes Care200326113148315214578253
   PubMed Web of Science ®Google Scholar
• LarsenTMToubroSAstrupAPPAR gamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?Int J Obes Relat Metab Disord200327214716112586994
   PubMed Web of Science ®Google Scholar
• SewterCPBlowsFVidal-PuigARegional differences in the response of human pre-adipocytes to PPAR gamma and RXR alpha agonistsDiabetes200251371872311872672
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAADOPT Study GroupGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy [erratum inN Engl J Med. 2007;356:1387–1388]N Engl J Med2006355232427244317145742
   PubMed Web of Science ®Google Scholar
• LokeYKSinghSFurbergCDLong-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysisCMAJ20091801323919073651
   PubMed Web of Science ®Google Scholar
• SchwartzAVSellmeyerDEVittinghoffEThiazolidinedione use and bone loss in older diabetic adultsJ Clin Endocrinol Metab20069193349335416608888
   PubMed Web of Science ®Google Scholar
• WanYChongLWEvansRMPPAR-gamma regulates osteoclastogenesis in miceNat Med200713121496150318059282
   PubMed Web of Science ®Google Scholar
• RetnakaranRDruckerDIntensive insulin therapy in newly diagnosed type 2 diabetesLancet200837196261725172618502278
   PubMed Web of Science ®Google Scholar
• KoroCEBowlinSJBourgeoisNFedderDOGlycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: A preliminary reportDiabetes Care2004271172014693960
   PubMed Web of Science ®Google Scholar
• BretzelRGNuberULandgrafWOnce-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trialLancet200837196181073108418374840
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200932119320318945920
   PubMed Web of Science ®Google Scholar